Conditions

Psoriasis

Outcome Measures

Primary Outcomes (7)

Lipoprotein composition differences-glucose
To assess differences in the blood concentration levels at baseline for glucose in moderate-to-severe pediatric psoriasis at baseline who begin systemically administered therapy vs: a) healthy controls; and b) patients with milder psoriasis.
one year
Lipoprotein composition differences-insulin
To assess differences in the blood concentration levels at baseline for insulin in moderate-to-severe pediatric psoriasis at baseline who begin systemically administered therapy vs: a) healthy controls; and b) patients with milder psoriasis.
one year
Lipoprotein composition differences-c-reactive protein
To assess differences in the blood concentration levels at baseline for c-reactive protein in moderate-to-severe pediatric psoriasis at baseline who begin systemically administered therapy vs: a) healthy controls; and b) patients with milder psoriasis.
one year
Lipoprotein composition differences-lipid concentration
To assess differences in the blood concentration levels at baseline for lipid concentration in moderate-to-severe pediatric psoriasis at baseline who begin systemically administered therapy vs: a) healthy controls; and b) patients with milder psoriasis.
one year
Lipoprotein composition differences-chemistry panel
To assess differences in the blood concentration levels at baseline for chemistry panel in moderate-to-severe pediatric psoriasis at baseline who begin systemically administered therapy vs: a) healthy controls; and b) patients with milder psoriasis.
one year
Lipoprotein composition differences-apolipoprotein
To assess differences in the blood concentration levels at baseline for apolipoprotein in moderate-to-severe pediatric psoriasis at baseline who begin systemically administered therapy vs: a) healthy controls; and b) patients with milder psoriasis.
one year
Lipoprotein composition differences-NMR
To assess differences in the blood concentration levels at baseline for NMR derived lipoprotein particle concentrations in moderate-to-severe pediatric psoriasis at baseline who begin systemically administered therapy vs: a) healthy controls; and b) patients with milder psoriasis.
one year

Study Arms (4)

Psoriasis patients to be treated only topically

Other: Fasting blood draw for lipid assessments

Psoriasis patients with moderate-to-severe psoriasis who begin

Other: Fasting blood draw for lipid assessments

Age-, sex- and BMI percentile-matched controls

Other: Fasting blood draw for lipid assessments

Patients being treated with isotretinoin for acne

Other: Fasting blood draw for lipid assessments

Interventions

Fasting blood draw for lipid assessmentsOther

Fasting blood draw for lipid assessments

Age-, sex- and BMI percentile-matched controlsPatients being treated with isotretinoin for acnePsoriasis patients to be treated only topicallyPsoriasis patients with moderate-to-severe psoriasis who begin

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age6 Years - 17 Years

Sexall

Healthy VolunteersYes

Age GroupsChild (0-17)

Sampling MethodNon-Probability Sample

Study Population

The investigators plan to recruit approximately 120 subjects total. Subjects will be divided into 4 groups: i) patients to be treated only topically (n=30); ii) patients with moderate-to-severe psoriasis who begin systemic treatment (n=30; \~15 DMARDs and 15 biologics); iii) age-, sex- and BMI percentile-matched controls (n=30); iv) patients being treated with isotretinoin for acne (n=30).

You may qualify if:

Sponsors & Collaborators

National Heart, Lung, and Blood Institute (NHLBI)
NIHcollaborator
National Psoriasis Foundation
Othercollaborator
Northwestern University

Study Sites (1)

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, 60611, United States

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples for lipids testing

MeSH Terms

Conditions

Psoriasis

Condition Hierarchy (Ancestors)

Skin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

Amy Paller, MD
Northwestern University
PRINCIPAL INVESTIGATOR

Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (7)

Study Arms (4)

Psoriasis patients to be treated only topically

Psoriasis patients with moderate-to-severe psoriasis who begin

Age-, sex- and BMI percentile-matched controls

Patients being treated with isotretinoin for acne

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (7)

Study Arms (4)

Psoriasis patients to be treated only topically

Psoriasis patients with moderate-to-severe psoriasis who begin

Age-, sex- and BMI percentile-matched controls

Patients being treated with isotretinoin for acne

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations